Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Non-Current Assets (2023 - 2025)

Historic Non-Current Assets for Immunome (IMNM) over the last 3 years, with Q3 2025 value amounting to $19.5 million.

  • Immunome's Non-Current Assets rose 5129.1% to $19.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $76.8 million, marking a year-over-year increase of 11902.21%. This contributed to the annual value of $18.9 million for FY2024, which is 39262.44% up from last year.
  • As of Q3 2025, Immunome's Non-Current Assets stood at $19.5 million, which was up 5129.1% from $18.9 million recorded in Q2 2025.
  • Immunome's Non-Current Assets' 5-year high stood at $19.6 million during Q1 2025, with a 5-year trough of $1.6 million in Q1 2023.
  • In the last 3 years, Immunome's Non-Current Assets had a median value of $11.9 million in 2024 and averaged $10.6 million.
  • Its Non-Current Assets has fluctuated over the past 5 years, first surged by 63600.46% in 2024, then skyrocketed by 5129.1% in 2025.
  • Quarter analysis of 3 years shows Immunome's Non-Current Assets stood at $3.8 million in 2023, then soared by 392.62% to $18.9 million in 2024, then increased by 2.92% to $19.5 million in 2025.
  • Its Non-Current Assets was $19.5 million in Q3 2025, compared to $18.9 million in Q2 2025 and $19.6 million in Q1 2025.